Log in

7630 IMPACT Therapeutics, Inc. HKEX · China

IMPACT Therapeutics (7630) news

IMPACT Therapeutics, Inc. is a public biotech or pharmaceutical company listed on HKEX under the ticker 7630, recorded under China. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest IMPACT Therapeutics news

We have not published a story on IMPACT Therapeutics yet. When there is news, it will appear here.

Questions about IMPACT Therapeutics

What is the ticker symbol of IMPACT Therapeutics?

IMPACT Therapeutics, Inc. trades under the ticker 7630 on HKEX.

Where is IMPACT Therapeutics listed?

IMPACT Therapeutics, Inc. is listed on HKEX.

Which country or territory is IMPACT Therapeutics listed under?

Our directory records IMPACT Therapeutics, Inc. under China.

What does IMPACT Therapeutics do?

Our directory classifies IMPACT Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of IMPACT Therapeutics?

The ISIN recorded for IMPACT Therapeutics, Inc. is CNE100007LG4.

Does aibio.space cover IMPACT Therapeutics?

aibio.space lists IMPACT Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to IMPACT Therapeutics?

Companies in our directory listed in the same country and business area as IMPACT Therapeutics: Shanghai Serum Bio-Technology Co., Hvsen Biotechnology Co., Hubei Goto Biopharm Group Co., Shanghai Rightongene Biotechnology Co., Hebei Changshan Biochemical Pharmaceutical Co., Hanx Biopharmaceuticals (Wuhan) Co..

Investor discussion: IMPACT Therapeutics

Members talk about IMPACT Therapeutics (7630). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at IMPACT Therapeutics, newest first. Each line links the filing it comes from.

  1. Financings

    Share or debt issue: (1) 2025 WORK REPORT OF THE BOARD OF DIRECTORS (2) ACCOUNTANT'S REPORT FOR THE YEAR ENDED DECEMBER 31, 2025 (3) 2025 PROFIT DISTRIBUTION PLAN (4) PROPOSED RE-APPOINTMENT OF AUDITOR (5) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION (6) PROPOSED GRANT OF ISSUE GENERAL MANDATE (7) PROPOSED GRANT OF REPURCHASE GENERAL MANDATE AND NOTICE OF ANNUAL GENERAL MEETING. Source

  2. Financings

    Share or debt issue: GLOBAL OFFERING. Source

Press releases

Headlines of IMPACT Therapeutics's own announcements, newest first. Each opens the full release on the newswire that carried it.

  1. HKEXnews

    VOLUNTARY ANNOUNCEMENT - POSTER PRESENTATION OF LATEST CLINICAL DATA FOR SENAPARIB AND PARP1-SELECTIVE INHIBITORS IMP1734 AND IMP1707 AT 2026 ESMO CONGRESS

  2. HKEXnews

    VOLUNTARY ANNOUNCEMENT - POSITIVE CHMP OPINION FOR SENAPARIB, AS POTENTIAL FIRST-LINE MAINTENANCE TREATMENT OF ADVANCED EPITHELIAL OVARIAN, FALLOPIAN TUBE, AND PRIMARY PERITONEAL CANCER

  3. HKEXnews

    VOLUNTARY ANNOUNCEMENT - INCLUSION IN THE STOCK LIST OF THE SHANGHAI-HONG KONG STOCK CONNECT AND THE SHENZHEN-HONG KONG STOCK CONNECT

  4. HKEXnews

    VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING BY THE EXECUTIVE DIRECTOR AND CHIEF EXECUTIVE OFFICER

  5. HKEXnews

    INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026

  6. HKEXnews

    VOLUNTARY ANNOUNCEMENT - INCLUSION AS A CONSTITUENT OF HANG SENG COMPOSITE INDEX

  7. HKEXnews

    VOLUNTARY ANNOUNCEMENT - IMPACT THERAPEUTICS ANNOUNCES IMP2794 AS A PRECLINICAL CANDIDATE (PCC), A HIGHLY KAT6A-SPECIFIC PROTAC FROM ITS PROPRIETARY TARGETED PROTEIN DEGRADATION PLATFORM

  8. HKEXnews

    PROFIT ALERT REDUCTION IN LOSS

  9. HKEXnews

    TERMS OF REFERENCE OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS

  10. HKEXnews

    VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT WITH PHARMANOVIA FOR SENAPARIB IN EUROPE, MIDDLE EAST AND NORTH AFRICA, AUSTRALIA AND NEW ZEALAND

  11. HKEXnews

    ARTICLES OF ASSOCIATION

  12. HKEXnews

    POLL RESULTS OF THE 2026 FIRST EXTRAORDINARY GENERAL MEETING HELD ON JULY 27, 2026 AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION

  13. HKEXnews

    VOLUNTARY ANNOUNCEMENT - IMPACT THERAPEUTICS ANNOUNCES IMP3201 AS A PRECLINICAL CANDIDATE (PCC), A FIRST-IN-CLASS CEACAM5-TARGETED DUAL-PAYLOAD ADC FROM ITS PROPRIETARY DUAL-PAYLOAD ADC PLATFORM

  14. HKEXnews

    VOLUNTARY ANNOUNCEMENT - ABSTRACT OF MULTIPLE RESEARCH RESULTS ACCEPTED FOR POSTER PRESENTATION AT 2026 ESMO CONGRESS

  15. HKEXnews

    NOTICE OF EXTRAORDINARY GENERAL MEETING

  16. HKEXnews

    (1) PROPOSED ADOPTION OF THE SHARE AWARD SCHEME AND AUTHORIZATION TO THE BOARD TO HANDLE MATTERS PERTAINING TO THE SHARE AWARD SCHEME; (2) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION; AND (3) NOTICE OF EXTRAORDINARY GENERAL MEETING

  17. HKEXnews

    PROPOSED ADOPTION OF THE SHARE AWARD SCHEME AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION

  18. HKEXnews

    BOOK CLOSURE PERIOD FOR THE 2026 FIRST EXTRAORDINARY GENERAL MEETING

  19. HKEXnews

    POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 25, 2026 AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION

  20. HKEXnews

    STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:7630 on TradingView.

Listing details

IMPACT Therapeutics, Inc. is a public biotech or pharmaceutical company listed on HKEX under the ticker 7630, recorded under China. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
IMPACT Therapeutics, Inc.
Ticker
7630
Listing
HKEX
Country or territory
China
Business scope
Biotechnology
ISIN
CNE100007LG4
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.